Deucravacitinib: First Approval

2022/11/01 by Sheridan M. Hoy · 27 citations
Immunology and Microbiology · Medicine · #Psoriasis: Treatment and Pathogenesis #Cytokine Signaling Pathways and Interactions #IL-33, ST2, and ILC Pathways

paper · pdf · doi:10.1007/s40265-022-01796-y

Cited by

• Late-Stage C–H Deuteration of Organic Compounds via Ligand-Enabled Palladium-Catalyzed Hydrogen Isotope Exchange
• Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions
• Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. [europepmc]
• A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. [europepmc]
• Targeted Therapy for SLE-What Works, What Doesn't, What's Next. [europepmc]
• Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. [europepmc]
• Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. [europepmc]
• The pyridazine heterocycle in molecular recognition and drug discovery. [europepmc]
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. [europepmc]
• The Genetic Susceptibility to Psoriasis and the Relationship of Linked Genes to Our Treatment Options. [europepmc]
• Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib. [europepmc]
• Synthesis and clinical application of new drugs approved by FDA in 2022. [europepmc]
• A Route for Investigating Psoriasis: From the Perspective of the Pathological Mechanisms and Therapeutic Strategies of Cancer. [europepmc]
• Modeling of horizontal pleiotropy identifies possible causal gene expression in systemic lupus erythematosus. [europepmc]
• The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. [europepmc]
• A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. [europepmc]
• Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults. [europepmc]
• Inflammation and Psoriasis: A Comprehensive Review. [europepmc]
• Inhibition of T-cell activity in alopecia areata: recent developments and new directions. [europepmc]
• SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis. [europepmc]
• Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets. [europepmc]
• New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis. [europepmc]
• Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling. [europepmc]
• Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature. [europepmc]
• Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease. [europepmc]
• Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research. [europepmc]
• Interventions in cytokine signaling: novel horizons for psoriasis treatment. [europepmc]